Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Unknown 1Recruiting 1Completed 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3Gastrointestinal 3Thoracic 2Gynecologic 2Genitourinary 2Dermatologic 2Other solid neoplasm 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 21Lung Neoplasms 10Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Skin Neoplasms 6Prostatic Neoplasms 5Neoplasm Metastasis 5Melanoma 5Head and Neck Neoplasms 5Urinary Bladder Neoplasms 4Colorectal Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Merkel Cell 4Breast Neoplasms 4Sarcoma 3Pancreatic Neoplasms 3Mycosis Fungoides 3Carcinoma, Squamous Cell 3Carcinoma, Hepatocellular 3Carcinoma, Basal Cell 3Adenocarcinoma 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Carcinoma, Anaplastic 2Rectal Neoplasms 2Oropharyngeal Neoplasms 2Mouth Neoplasms 2Mesothelioma, Malignant 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2

Interventions

Sorafenib 131lenvatinib 115Bevacizumab 88Radiosurgery 69atezolizumab 55sintilimab 54Nivolumab 51durvalumab 43Hepatectomy 43Fluorouracil 42apatinib 41Oxaliplatin 41camrelizumab 38Radiofrequency Ablation 38pembrolizumab 36Radiotherapy 36tislelizumab 35Leucovorin 31Magnetic Resonance Spectroscopy 30Immune Checkpoint Inhibitors 28Doxorubicin 28Folfox protocol 26tremelimumab 25regorafenib 25Cisplatin 20spartalizumab 19donafenib 19Gemcitabine 19Cyclophosphamide 19toripalimab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Hepatocellular × cemiplimab × Clear all
NCT06923761 2026-01-28

EMITT-1

Grey Wolf Therapeutics

Phase 1/2 Recruiting
300 enrolled
GastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Lung Neoplasms, Neoplasms

NCT04157985 2025-12-11

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

University of Pittsburgh

Phase 3 Completed
161 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Jules Bordet Institute

Phase 2 Unknown
441 enrolled
BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡